Clinical and biologic features, treatment, and clinical outcome in 25 patients with ALL1/AF4-positive acute lymphoblastic leukemia
| Patient . | Age (y)/ Sex . | WBC (109/L) . | Karyotype . | ALL1 Gene Status . | Immunophenotype . | Treatment . | Treatment Resp HR/MR . | Clinical Outcome . |
|---|---|---|---|---|---|---|---|---|
| 1 | 29/F | 380 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0288 | Yes/yes | 1st CCR 96+ mo |
| 2 | 52/F | 328 | 46 XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0288 | Yes/yes | 1st CCR 90+ mo |
| 3 | 33/F | 17 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B* | GIMEMA 0288 | Yes/no | Rel 10 mo; died 12 mo |
| 4 | .3/F | 17 | 46;XX,t(4;11)(q21;q23) | R | Pre-pre B* | AIEOP 9503 | Yes/no | Rel 9 mo; died 16 mo |
| 5 | 71/F | 126 | NE | R | Common | VCR + IDA + PDN† | Yes/no | Rel 4 mo; died 11 mo |
| 6 | 21/F | 290 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0394 | Yes/yes | Rel 5 mo; died 15 mo |
| 7 | 26/F | 270 | NE | R | Pre-pre B | GIMEMA 0394 | Yes/no | Rel 18 mo; died 19 mo |
| 8 | .8/M | 34 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | AIEOP 9503 | Yes/yes | Rel 14 mo; died 20 mo |
| 9 | 38/M | 22.4 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 6 mo; died 8 mo |
| 10 | 44/F | 93 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 7 mo; died 8 mo |
| 11 | 16/M | 21.6 | 46,XY,17p- | R | Pre-pre B | GIMEMA 0496 | Yes/yes | Rel 9 mo; 2nd CCR 28+ mo |
| 12 | 42/F | 8.6 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 6 mo; 2nd CCR 12+ mo |
| 13 | 21/M | 131.5 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/yes | Rel 22 mo; died 25 mo |
| 14 | 58/F | 227 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 8 mo; died 12 mo |
| 15 | 39/M | 274 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 4 mo; died 9 mo |
| 16 | 49/M | 19.6 | NE | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 11 mo; died 13 mo |
| 17 | 25/M | 41.2 | 46,XY | R | Pre-pre B | GIMEMA 0496 | Yes/yes | Rel 14 mo; died 17 mo |
| 18 | 49/F | 41.4 | NE | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 14 mo; died 15 mo |
| 19 | 28/M | 281 | NE | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 3 mo; died 4 mo |
| 20 | 47/M | 60 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/yes | 1st CCR 14+ mo |
| 21 | 47/M | 135 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/yes | 1st CCR 12+ mo |
| 22 | 60/F | 112 | 46,XX,t(4;11)(q21;q23) | ND | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 6 mo; died 9 mo |
| 23 | 53/F | 75 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/yes | 1st CCR 7+ mo |
| 24 | .1/M | 128 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | INTERFANT 99 | Yes/yes | 1st CCR 3+ mo |
| 25 | 40/F | 41 | ND | R | Pre-pre B | GIMEMA 0496 | Yes/no | 1st CCR 3+ mo |
| Patient . | Age (y)/ Sex . | WBC (109/L) . | Karyotype . | ALL1 Gene Status . | Immunophenotype . | Treatment . | Treatment Resp HR/MR . | Clinical Outcome . |
|---|---|---|---|---|---|---|---|---|
| 1 | 29/F | 380 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0288 | Yes/yes | 1st CCR 96+ mo |
| 2 | 52/F | 328 | 46 XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0288 | Yes/yes | 1st CCR 90+ mo |
| 3 | 33/F | 17 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B* | GIMEMA 0288 | Yes/no | Rel 10 mo; died 12 mo |
| 4 | .3/F | 17 | 46;XX,t(4;11)(q21;q23) | R | Pre-pre B* | AIEOP 9503 | Yes/no | Rel 9 mo; died 16 mo |
| 5 | 71/F | 126 | NE | R | Common | VCR + IDA + PDN† | Yes/no | Rel 4 mo; died 11 mo |
| 6 | 21/F | 290 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0394 | Yes/yes | Rel 5 mo; died 15 mo |
| 7 | 26/F | 270 | NE | R | Pre-pre B | GIMEMA 0394 | Yes/no | Rel 18 mo; died 19 mo |
| 8 | .8/M | 34 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | AIEOP 9503 | Yes/yes | Rel 14 mo; died 20 mo |
| 9 | 38/M | 22.4 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 6 mo; died 8 mo |
| 10 | 44/F | 93 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 7 mo; died 8 mo |
| 11 | 16/M | 21.6 | 46,XY,17p- | R | Pre-pre B | GIMEMA 0496 | Yes/yes | Rel 9 mo; 2nd CCR 28+ mo |
| 12 | 42/F | 8.6 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 6 mo; 2nd CCR 12+ mo |
| 13 | 21/M | 131.5 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/yes | Rel 22 mo; died 25 mo |
| 14 | 58/F | 227 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 8 mo; died 12 mo |
| 15 | 39/M | 274 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 4 mo; died 9 mo |
| 16 | 49/M | 19.6 | NE | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 11 mo; died 13 mo |
| 17 | 25/M | 41.2 | 46,XY | R | Pre-pre B | GIMEMA 0496 | Yes/yes | Rel 14 mo; died 17 mo |
| 18 | 49/F | 41.4 | NE | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 14 mo; died 15 mo |
| 19 | 28/M | 281 | NE | R | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 3 mo; died 4 mo |
| 20 | 47/M | 60 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/yes | 1st CCR 14+ mo |
| 21 | 47/M | 135 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/yes | 1st CCR 12+ mo |
| 22 | 60/F | 112 | 46,XX,t(4;11)(q21;q23) | ND | Pre-pre B | GIMEMA 0496 | Yes/no | Rel 6 mo; died 9 mo |
| 23 | 53/F | 75 | 46,XX,t(4;11)(q21;q23) | R | Pre-pre B | GIMEMA 0496 | Yes/yes | 1st CCR 7+ mo |
| 24 | .1/M | 128 | 46,XY,t(4;11)(q21;q23) | R | Pre-pre B | INTERFANT 99 | Yes/yes | 1st CCR 3+ mo |
| 25 | 40/F | 41 | ND | R | Pre-pre B | GIMEMA 0496 | Yes/no | 1st CCR 3+ mo |
WBC indicates white blood cells; Resp, response; HR, hematologic remission; MR, molecular remission; R, rearranged; Pre-pre B, HLDR+, CD19+, CD10−; CCR, continuous complete remission; Rel, relapse; NE, not evaluable; common, HLA-DR+, CD19+, CD10+; and ND, karyotyping not done.
Coexpression of myeloid antigen(s).
Vincristine, idarubicin, and prednisone.